Please login to the form below

Not currently logged in
Email:
Password:

Medicis rated 'Strong Sell' on weak dermatology sales

Analysts give US-based Medicis Pharmaceutical a "Strong Sell" rating after dermatology sales disappoint

Matrix Research analysts have given US-based Medicis Pharmaceutical a "Strong Sell" rating.

Analysts say that the company's dermatology sales had risen only four per cent over the eight-quarter period ended June 2007. With a 40 per cent rise in Medicis' capital over the period, the company's return on capital has declined significantly.

In August 2007, Swedish biotechnology company Q-Med said it was eyeing a merger with Medicis.

Q-Med's CEO, Bengt Agerup, who owns 47.5 per cent of the firm, said that a union with Medicis made "industrial sense". The company had partnered with Medicis on the marketing of the Swedish firm's cosmetic filler Restylane.

No concrete merger talks were ongoing at the time, but if the valuations of the company changed, talks might be initiated, added Agerup.

17th September 2007

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
wearable health tech
A cultural shift in clinical research
Research organisations across the board are experimenting with new technologies...

Infographics